The plasminogen activator inhibitor-1 (PAI-1) blocks the activation of plasmin(ogen), an extracellular protease vital to cancer invasion. PAI-1 is like the corresponding plasminogen activator uPA (urokinase-type plasminogen activator) consistently expressed in human breast cancer. Paradoxically, high levels of PAI-1 as well as uPA are equally associated with poor prognosis in cancer patients. PAI-1 is thought to play a vital role for the controlled extracellular proteolysis during tumor neovascularization. We have studied the effect of PAI-1 deficiency in a transgenic mouse model of metastasizing breast cancer. In these tumors, the expression pattern of uPA and PAI-1 resembles that of human ductal breast cancer and plasminogen is required for efficient metastasis. In a cohort of 63 transgenic mice that were either PAI-1-deficient or wild-type sibling controls, primary tumor growth and vascular density were unaffected by PAI-1 status. PAI-1 deficiency also did not significantly affect the lung metastatic burden. These results agree with the virtual lack of spontaneous phenotype in PAI-1-deficient mice and humans and may reflect that the plasminogen activation reaction is not rate limiting for tumor vascularization and metastasis, or that there is a functional redundancy between PAI-1 and other inhibitors of the uPA/plasmin system, masking the effect of PAI-1 deficiency.
Introduction
Tissue remodeling during normal and pathological processes such as embryogenesis (Werb et al., 1999) , mammary gland morphogenesis (Werb et al., 1996; Lund et al., 2000) , wound healing (Lund et al., 1999) , angiogenesis (Pepper, 2001 ) and cancer invasion (Johnsen et al., 1998; Matrisian, 1999; Stamenkovic, 2000) is finely regulated by the presence of extracellular matrixdegrading proteases and their corresponding inhibitors. Among the various extracellular proteolytic cascades, the plasminogen activation (PA) system has a welldocumented role in most of these processes, including cancer invasion (Rmer et al., 1996; Bugge et al., 1998; Johnsen et al., 1998; Lund et al., 2000) .
The PA system (Tapiovaara et al., 1996; Andreasen et al., 2000; Lijnen, 2001; Parfyonova et al., 2002) leads to generation of the broad-spectrum serine protease plasmin from its circulating zymogen. Plasminogen is proteolytically activated by specific activators. The urokinase-type plasminogen activator (uPA), the most cancer relevant plasminogen activator, is synthesized as the zymogen pro-uPA. Pro-uPA binds with high affinity to a cell surface-bound receptor, the urokinase receptor (uPAR). Receptor binding of pro-uPA concomitant with cell surface binding of plasminogen strongly enhances the overall reaction leading to plasmin formation and at the same time localizes plasmin activity to cell surfaces. The PA cascade is inhibited at several levels by serpin-type protease inhibitors. The main plasmin inhibitor is a 2 -antiplasmin, while plasmin formation is inhibited by at least two plasminogen activator inhibitors, PAI-1 and PAI-2. Of these, PAI-1 is considered to be the primary physiological extracellular inhibitor of plasminogen activation. It rapidly inhibits both free and receptor-bound uPA as well as the tissuetype plasminogen activator (tPA), the main thrombolytic plasminogen activator. PAI-1 that is not complexed with a plasminogen activator has a high affinity for vitronectin, an interaction that may play a role in cellular adhesion and migration (Deng et al., 1996; Loskutoff et al., 1999) .
uPA, uPAR and also PAI-1 are consistently expressed in invasive areas of human breast cancer Bianchi et al., 1995; Nielsen et al., 1996) , and also in a wide variety of other human cancers, including carcinomas of the colon, lung, ovary and prostate (Hewitt and Dan, 1996; Andreasen et al., 1997) . In addition to the epithelial component, carcinomas consist of a variety of stromal cells, such as fibroblasts, endothelial cells and macrophages. The components of the uPA system are often expressed by stromal cells rather than the epithelial cancer cells, in a pattern that is characteristic for each type of cancer (Hewitt and Dan, 1996; Johnsen et al., 1998; Almholt and Johnsen, in press ). In ductal mammary carcinoma, uPA is thus mainly expressed by myofibroblasts (Nielsen et al., 1996 (Nielsen et al., , 2001b , uPAR by macrophages Bianchi et al., 1994) , while PAI-1 immunoreactivity is present in fibroblasts, endothelial cells, macrophages and some cancer cells (Bianchi et al., 1995) .
In breast cancer and several other types of cancer, high levels of uPA and uPAR in the cancer tissue are strongly associated with poor prognosis, in agreement with the proposed enhancing role of both molecules in matrix degradation and cancer invasion (Duffy et al., 1988; Grndahl-Hansen et al., 1993 Look et al., 2002; Riisbro et al., 2002) . Surprisingly, high levels of the inhibitory molecule PAI-1 in breast cancer tissue are also strongly and consistently associated with poor prognosis, that is, short survival of the patients (Ja¨nicke et al., 1991; Grndahl-Hansen et al., 1993; Harbeck et al., 1999; Look et al., 2002) , and a similar association has been found in several other types of cancer (Nekarda et al., 1994; Pedersen et al., 1994; Andreasen et al., 1997) . The reason for this apparently paradoxical relation between PAI-1 and prognosis has not yet been clarified.
In spite of the thorough biochemical knowledge of PAI-1 and its interaction with uPA, tPA and vitronectin, little is known of the nonthrombolytic functions of this inhibitor in vivo. In patients with complete PAI-1 deficiency, the clinical manifestations appear to be restricted to abnormal bleeding after trauma (Fay et al., 1997) . In PAI-1 gene-deficient mice there is only a mild acceleration of thrombolysis, but no apparent spontaneous extravascular abnormalities, a finding that may reflect that other protease inhibitors compensate for the lack of PAI-1 (Carmeliet et al., 1993a, b) . However, it has been reported that host PAI-1 deficiency impairs tumor angiogenesis in both a transplanted murine skin cancer model (Bajou et al., 1998 ) and a transplanted murine fibrosarcoma (Gutierrez et al., 2000) .
To obtain new information on the role of PAI-1 in breast cancer, we have now studied the effect of PAI-1 gene deficiency in transgenically induced breast cancer, thus avoiding the inherent problems of transplanting cancer cells, which themselves may produce PAI-1, into PAI-1-deficient mice. In this transgenic model, the polyomavirus middle T antigen (PymT) under control of a mouse mammary tumor virus long-terminal repeat promoter (MMTV-LTR) induces breast tumors with 100% penetrance (Guy et al., 1992) . These are similar to human mammary adenocarcinoma, both with respect to histology and to expression of uPA and PAI-1 in stromal cells adjacent to invasive cancer cells. Furthermore, all the mice get lung metastases (Guy et al., 1992; Bugge et al., 1998) , and we have previously found that the plasminogen activation system plays a role in metastasis, which is considerably delayed in plasminogen-deficient mice (Bugge et al., 1998) . We here use a recently developed stereological method (Nielsen et al., 2001a ) for a precise quantitation of the effect of PAI-1 deficiency on metastasis.
Materials and methods

Mice
Heterozygous FVB/N-TgN(MMTVPyVT)634 Mul (Guy et al., 1992) (hereafter FVB-PymT) male mice were mated with PAI-1 heterozygous females (Carmeliet et al., 1993a) , which had been backcrossed for eight generations onto the C57BL/ 6J strain (B6-Pai-1 þ /À (N8)). Their male F1 offspring were mated with the B6-Pai-1 þ /À (N8) females to generate the B6,FVB-PymT,Pai-1
þ / þ mice used throughout the study, all of which were siblings. All pups were weaned at age 21-23 days, genotyped and recaged randomly with six mice in each cage. Tissue for in situ hybridization studies was obtained from FVB-PymT and non-transgenic FVB females unless otherwise stated. All analyzed mice were female virgins. All animal experiments were approved by the Danish Animal Experiments Inspectorate. The mice were housed in a restricted access facility and fed a regular chow. A concurrent FELASA compliant health report revealed no infections.
Genotyping
Chromosomal DNA from an approx. 2-mm piece of tail tip was isolated essentially as described (Laird et al., 1991) . Genotyping was performed by combining in a single PCR reaction a primer pair specific for the MMTV-PymT transgene (Bugge et al., 1998) with three primers specific for the PAI-1 alleles. mPAI1.1p (TTC ATG CCC TCT GGT CGC TG) upstream and mPAI1.2 m (CTC CCT CCC TCC CAG TGA CTT G) downstream of the 5 0 insertion point of the targeting vector (i.e. the XhoI(911) site in the PAI-1 gene promoter region, GenBank: M33961) amplified a 349 bp band specific for the endogenous allele. The 5 0 end of the inserted DNA fragment in the disrupted PAI-1 allele (Carmeliet et al., 1993a) is a XhoI-BamHI neomycin cassette from pPNT (Tybulewicz et al., 1991) . mPAI1.1p and mPGK2 m (GCC TTG GGA AAA GCG CCT C) in the mouse phosphoglycerate kinase-1 promoter (GenBank: M18735) within this neomycin cassette amplified an approx. 220 bp band specific for the disrupted allele. In all, 35 cycles of PCR with T(anneal) ¼ 601C were performed using HotStarTaq (Qiagen, Cat# 203445, Hilden, Germany) as described by the manufacturer.
Tumor growth and tissue processing
Mice were examined weekly for mammary tumor onset by palpation for nodules in all 10 mammary glands by a person unaware of their genotype. The date of first positive diagnosis was taken as the date the first tumor was found, provided that the diagnosis was confirmed the following week. Tumor volume was assessed weekly by measuring the length and width of individual tumors with a caliper. The volume of each tumor was approximated as the volume of an oblong spheroid of the measured length (l ) and width (w) that is V(tumor) ¼ plw 2 /6 (Euhus et al., 1986) . The individual tumor volumes were summed to give the total tumor volume in each mouse. To minimize final tumor size variation, the mice were killed 5-6 days after the total tumor burden in each individual mouse exceeded a preset threshold size of 1.5 cm 3 . The mice were anesthetized as described (Lund et al., 2000) and a tumor sample was collected for RNA analysis and immediately PAI-1 deficiency in transgenic mammary cancer K Almholt et al placed on dry ice. Hereafter, the mice were perfusion fixed with 10 ml cold Dulbecco's phosphate-buffered saline (PBS) (Biochrom, Cat# L1825, Berlin, Germany) followed by 10 ml freshly prepared cold PBS with 4% paraformaldehyde (Merck, Darmstadt, Germany). Their lungs were removed, air-evacuated, fixed and cryoembedded for metastasis quantification as described (Nielsen et al., 2001a) . Tumor tissue for in situ hybridization and CD34 staining was removed, cut into B5-mm thick slabs for optimal access of fixative and placed in PBS with 4% paraformaldehyde overnight at 41C before automated paraffin embedding (Thermo Shandon, Cat# 75200011, Pittsburgh, PA, USA). Two slabs of the largest tumor from each mouse were prepared for CD34 staining.
Northern blotting
Frozen tumor tissue was ground with a mortar and pestle and disrupted with a mechanical tissue homogenizer. Total RNA was extracted using the RNeasy kit (Qiagen, Cat# 75142) as described by the manufacturer. A measure of 10 mg of each sample was denatured and electrophoresed by the glyoxal/ DMSO method (Brown and Mackey, 1997 ) and transferred to a nylon membrane (Bio-Rad, Cat# 162-0196, Hercules, CA, USA) by upward capillary transfer in 10 mm NaOH for 2 h. The RNA was UV-crosslinked to the membrane and incubated overnight at 681C with a [ 32 P]UTP-labeled RNA probe at 10 6 c.p.m./ml in 50% formamide, 0.12 m NaH 2 PO 4 pH 7.0, 0.25 m NaCl, 7% SDS, and 0.1 mg/ml yeast tRNA (GibcoBRL, Cat# 15401-029). The membrane was washed the following day at 651C with 0.1% SDS in saline citrate buffers (SSC) of decreasing strength, and exposed on a phophorimager screen.
Radiolabeled RNA probes were transcribed from plasmids containing fragments of various mouse cDNAs and hybridized separately to identical membranes. The plasmids were pmuPA10 K that contains a 201-608 EcoRI fragment of uPA (GenBank: X02389) in pBluescript KS þ ; the plasmid pKaA229 that contains an EcoRI(804)-2497 fragment of tPA (GenBank: J03520) in pT7T3-18; the Image Consortium Clone ID 1226790 (Lennon et al., 1996) that contains a fragment of PAI-2; the plasmid pmPAI-1 03 K that contains a PstI(338)-XhoI(857) fragment of PAI-1 (GenBank: M33960) in pBluescript KS þ ; and the plasmid pKaA127 that contains a 51-1033 fragment of glyceraldehyde-3-phosphate dehydrogenase (GAPDH; GenBank: M32599) in pCR2.1. The plasmid pmuPA10 K was subcloned from pmuPA10 (Kristensen et al., 1991), while pKaA229 was subcloned from pTAM50, which was kindly provided by Dr RJ Rickles. Each plasmid was linearized in order to transcribe fragments of 408-821 bp.
In situ hybridization PAI-1 mRNA was detected in tissue samples using [ 35 S]UTPlabeled RNA probes at 10 5 c.p.m./ml on 5-mm thick paraffin sections essentially as described . The sections were developed after 2 weeks of exposure and counterstained lightly with hematoxylin and eosin (H&E). The RNA probes were transcribed in antisense or sense orientation from two nonoverlapping fragments of mouse PAI-1 cDNA (Prendergast et al., 1990) in pBluescript KS þ : plasmids pmPAI-1 02 (8-338 PstI fragment) and pmPAI-1 03 K.
Vascular length density quantification
Paraffin sections (5-mm) were dried overnight at room temperature, deparaffinized in xylene and hydrated through graded ethanol solutions. The sections were boiled twice for 5 min in 10 mm citric acid pH 6.0 in a microwave oven to demask the antigen, then slowly cooled to room temperature, where all the following steps were performed. Endogenous peroxidases were exhausted by 15 min incubation in fresh 1% H 2 O 2 . The sections were rinsed in tap water, transferred to Tris-buffered saline (50 mm Tris pH 7.6, 150 mm NaCl) with 0.5% Triton X-100 and mounted in disposable immunostaining chambers (Thermo Shandon, Cat# 7211013). Prior to incubation, the previously characterized monoclonal rat anti-mouse CD34 antibody (Garlanda et al., 1997) (HyCult Biotechnology, Cat# HM1015, Uden, The Netherlands) was biotinylated (non-chemically) using the DAKO ARK kit (DAKOCytomation, Cat# K3955, Glostrup, Denmark) as described by the manufacturer. Although intended for mouse antibodies, the ARK kit crossreacts with rat antibodies as stated by the manufacturer. The sections were incubated with the biotinylated anti-CD34 antibody (final conc. 3.3 mg/ ml) for 2 h. Addition of streptavidin-conjugated peroxidase and color development with 3,3-diaminobenzidine Á 4HCl (DAB) was performed as described in the ARK kit. The sections were lightly counterstained with hematoxylin, rinsed in tap water, removed from the staining chambers and mounted with glycergel (DAKOCytomation, Cat# C563). A mouse monoclonal antitrinitrophenyl antibody (Shulman et al., 1978) was biotinylated and used in parallel as a negative control.
Vascular length density L V (vasc/tumor) (1) was estimated with an unbiased stereological technique ) on two CD34-stained tumor sections from each mouse. Vascular profiles Q(vasc) were identified by two criteria: positive staining for CD34 and morphological resemblance of a vessel. P(tumor) is a point count used to estimate the analyzed tumor tissue area; a(p) is the area associated with each point.
The average radius of living tumor around a vessel r r(tumor/vasc) (2) (including the vessel radius) was also calculated.
Stereological quantification of lung metastasis volume Gundersen et al. described the general principles behind stereological volume estimations (Gundersen et al., 1988) . The estimate of total metastasis volume in each set of lungs was obtained using a recently developed unbiased and precise computer-assisted stereological technique (Nielsen et al., 2001a) . Briefly, the cryoembedded lungs were cut into slabs of 2-mm thickness (t) to obtain 5-8 evenly distributed crosssections, which were then reembedded face down in a single block, sectioned and H&E stained. All observations were done by a person unaware of the genotype of the analyzed specimens. The total metastasis volume V(met) (3) was calculated from a point count P(met) used to estimate the area of metastatic foci in the sections. a(p) is the area associated with each point.
V ðmetÞ ¼ taðpÞ X PðmetÞ ð 3Þ
Statistical analyses
Hypotheses on differences between genotypes with respect to tumor latency, age at sacrifice, final tumor volume and vascular length density were tested by Student's t-tests. 
Results
Histology and PAI-1 expression in MMTV-PymTinduced tumors
Tissue was obtained from 13-15 week old FVB-PymT females unless otherwise stated. The MMTV-PymT tumors resembled human mammary adenocarcinomas as previously described (Guy et al., 1992; Bugge et al., 1998; Maglione et al., 2001 ). There were no obvious morphological differences in the analyzed late stage tumors as a consequence of PAI-1 deficiency. We used in situ hybridization to analyze the expression pattern of PAI-1 mRNA in MMTV-PymT-induced mammary tumors and lung metastases. In 10 of 10 cases, we detected PAI-1 mRNA in stromal cells within and surrounding the primary tumors, usually concentrated at the periphery (including invasive fronts) ( Figure   1a-d) . In no cases could we detect PAI-1 mRNA in the neoplastic epithelial cells. Similarly, in six of nine cases analyzed, we detected PAI-1 mRNA in stromal cells within and surrounding metastatic foci in the lungs (Figure 1e-h) . Again, in no case could we detect PAI-1 mRNA in the epithelial cells of the metastases. In three sets of lungs, two of which also contained PAI-1 mRNA positive metastases, we additionally found PAI-1 mRNA in a number of scattered cells that were not associated with metastatic foci (data not shown). We detected very little or no PAI-1 expression in lungs from age-and background-matched nontransgenic FVB mice (n ¼ 3; data not shown). We confirmed the hybridization specificity with three different approaches: we did not observe any PAI-1 mRNA signal in primary tumors from B6,FVB-PymT,Pai-1 À/À mice (n ¼ 2; data not shown), and on adjacent sections of every tissue analyzed, we obtained similar results with a nonoverlapping antisense RNA probe (data not shown) and saw no signal with the corresponding sense probes (Figure 1c  and g ). To exclude strain-specific differences, we confirmed that tumors from B6,FVB-PymT,Pai-1 þ / þ mice stained positive for PAI-1 mRNA (data not shown).
Tumor growth and vascularity in PAI-1 gene-deficient mice
In order to determine the influence of PAI-1 deficiency on MMTV-PymT-induced tumors, we generated a cohort consisting of PymT,Pai-1 Figure 1 Expression of PAI-1 mRNA in MMTV-PymT-induced mammary tumors and lung metastases. PAI-1 mRNA was detected by in situ hybridization in primary tumors (a-b) and lung metastases (e-f) with a PAI-1 antisense RNA probe. Staining is seen as silver grains in the bright field images (a, e) and more readily with dark field illumination as white reflections (b, f). Hybridizations with the corresponding sense RNA probe were negative (c, g). PAI-1 mRNA was abundant at the invasive front of the primary MMTV-PymTinduced breast tumors (corresponding arrows in a, b). PAI-1 mRNA was also seen in scattered cells in some lung metastases, here shown in a large surface metastasis (corresponding arrows in e, f). Higher magnifications of the areas indicated in a and e illustrate that PAI-1 mRNA was primarily found in stromal cells in the connective tissue of both the primary tumors (d) and lung metastases (h). Sections were H&E counterstained. Bars are 200 mm (a, e), 50 mm (d), and 25 mm (h) PAI-1 deficiency in transgenic mammary cancer K Almholt et al each mouse weekly. All the MMTV-PymT-transgenic mice developed tumors irrespective of their PAI-1 status. The primary tumors of PAI-1-deficient and control mice first appeared at ages 61713 and 63711 days, respectively. Thus, there was no significant difference in the age at tumor detection (t-test, P ¼ 0.43; Figure 2 ). As detailed in the 'Materials and Methods' section, the mice were killed as soon as their total tumor volume had passed a threshold level of 1.5 cm 3 . This was done to ensure that a possible effect on tumor vascularity and metastatic burden was not simply a reflection of different primary tumor size in the animals. The PAI-1-deficient and control mice passed the preset threshold at average ages of 122715 and 126712 days, respectively; this difference was not significant (t-test, P ¼ 0.22; Figure 2 ). As a result of this strategy, the primary tumor volumes at the day of sacrifice were very similar: 2.6270.6 cm 3 in PAI-1-deficient vs 2.5570.9 cm 3 in control mice (t-test, P ¼ 0.72).
The total tumor volume of each mouse was measured weekly and transformed logarithmically before calculating their average 7 s.d. (Figure 3 ). The exponential tumor growth rate of each mouse was estimated by linear regression of all (logarithmically transformed) tumor measurements from the first time the mouse presented with a palpable tumor and until it was killed. The exponential tumor growth rates of PymT,Pai-1 À/À mice were on average slightly higher than those of PymT,Pai-1 þ / þ mice, but they did not differ significantly (t-test, P ¼ 0.11). The average tumor volume doubling times were 6.871.7 days in PAI-1-deficient vs 7.271.4 days in control mice.
As earlier reports have shown an effect of PAI-1 deficiency on vascularization in some transplanted tumor model systems (Bajou et al., 1998 Gutierrez et al., 2000) , we also analyzed the tumor vascularity. A palpable tumor does not usually develop in all 10 mammary glands. Therefore, it would not be possible to analyze a tumor from the same gland in all mice. Instead, we used the largest tumor from each mouse. The tumor vascular density was quantified on two CD34-stained sections from each tumor (Figure 4) . All of the analyzed tumors were judged to be adequately and evenly fixed, as none of them displayed a conspicuous absence of CD34 staining. The vascular length density (mm vessel/mm 3 ) in the analyzed primary tumors was slightly, but not significantly, decreased in PAI-1-deficient mice to 68719 mm À2 vs 77723 mm À2 in control mice (t-test, P ¼ 0.13; Figure 4 ). From this we calculated the average radius of living tumor around each vessel (including the vessel radius) to be 70710 mm in PAI-1-deficient vs 6679 mm in control mice. 
Lung metastasis in PAI-1 gene-deficient mice
The similar primary tumor burdens allowed unbiased comparison of lung metastases. Lungs with visible surface metastases at necropsy were rare in the cohort, regardless of PAI-1 status. The total volume of lung metastases in each mouse was quantified by stereological analysis of 5-8 evenly spaced H&E-stained crosssections of its lungs (Nielsen et al., 2001a) . Using this technique, we found 100% (24/24) incidence of lung metastases in PAI-1-deficient mice vs 92% (36/39) in control mice. This difference was not significant (Fisher exact, P ¼ 0.28). Lungs from the nontransgenic but sibling Pai-1 þ / þ (n ¼ 9) and Pai-1 À/À (n ¼ 11) mice were processed in parallel and included randomly among the analyzed lungs; none were scored positive for metastases.
The geometric average metastasis volume was increased to 0.165 mm 3 in PAI-1-deficient mice compared with 0.059 mm 3 in control mice ( Figure 5 ). This seemingly large difference is not significant (t-test, P ¼ 0.23), reflecting inherent wide variation in metastatic burdens in mice of the same genotype.
Expression of PAI-2, uPA and tPA in PAI-1-deficient and wild-type tumors
To address the possibility that other components of the plasminogen activation system may be up-or downregulated as a consequence of PAI-1 deficiency, we performed a Northern blot analysis of the expression level of PAI-2, uPA and tPA mRNAs in primary breast tumors from five PymT,Pai-1 À/À and five PymT,Pai-1 þ / þ mice ( Figure 6 ). PAI-1-deficient and -proficient tumor samples for RNA extraction were processed in parallel and chosen in such a way that they pairwise came from mice killed on the same day. There were no apparent differences in the expression level of PAI-2, uPA, or tPA that could be related to PAI-1 status. The RNA samples were also hybridized with a PAI-1 probe confirming that PAI-1 mRNA was easily detected in PymT,Pai-1
tumors and undetectable in PymT,Pai-1 À/À tumors ( Figure 6 ).
Discussion
We have analyzed the consequences of PAI-1 deficiency on tumor development, growth, vascularity and metastasis in a transgenic mouse model. In this model, the MMTV-PymT transgene results in the development of mammary tumors in all virgin females and virtually all tumors eventually metastasize to the lungs (Guy et al., 1992; Bugge et al., 1998) . Both uPA (Bugge et al., 1998) and PAI-1 are present in stromal cells in these tumors, as they are in human ductal adenocarcinomas of the breast (Wolf et al., 1993; Bianchi et al., 1995; Nielsen et al., 1996 Nielsen et al., , 2001b , and inactivation of the plasminogen gene leads to reduced lung metastasis, thus demonstrating a role of the PA system in this process (Bugge et al., 1998) .
By crossing a PAI-1-null allele (Carmeliet et al., 1993a) into the MMTV-PymT model, we generated a cohort of mice in which we could compare tumor incidence, latency and growth rates while the animals were still alive. Tumor vascularity and lung metastasis burden were determined after killing of the mice, when their primary tumor volume had reached a previously set threshold value. Thus, these parameters would not be influenced by variations in the size of the primary tumors. Analysis of a total of 24 PymT,Pai-1 À/À mice and 39 PymT,Pai-1 þ / þ siblings showed no significant differences between PAI-1-deficient and wild-type animals in any of the analyzed parameters. We also found no evidence that PAI-1 deficiency lead to a compensatory increase in the alternative inhibitor PAI-2 or a Expressions of PAI-1 and GAPDH mRNAs were included as controls PAI-1 deficiency in transgenic mammary cancer K Almholt et al decrease in either of the plasminogen activators uPA and tPA. Such expression differences could potentially account for the lack of phenotype in the PAI-1-deficient mice. We therefore conclude that PAI-1 deficiency by itself does not significantly influence tumorigenesis, tumor growth, vascularization or metastasis in the MMTV-PymT model. These findings agree well with the virtual lack of detectable spontaneous phenotype in PAI-1 genedeficient mice (Carmeliet et al., 1993a, b) , which indicates that development, growth and reproduction take place normally in the absence of PAI-1. Also in man, PAI-1 deficiency is without clinical manifestations, except for mild bleeding disorders (Fay et al., 1997) . Nevertheless, plasminogen activation is thought to play a role in processes like implantation (Sappino et al., 1989; Hofmann et al., 1994; Feng et al., 2001) , embryogenesis (Sappino et al., 1991; Ha¨ckel et al., 1995) and angiogenesis (Pepper, 2001) , and PAI-1 is expressed during these processes (Hofmann et al., 1994; Ha¨ckel et al., 1995; Pepper et al., 1996; Feng et al., 2001) .
Initially one might expect that PAI-1 deficiency increases plasminogen activation and thereby stimulates processes in which plasminogen activation is involved, such as metastasis in the MMTV-PymT model. However, it should be noted that the plasminogen activation reaction is only one step in a complex cascade of reactions that involve several additional steps, such as receptor binding of pro-uPA, cell surface binding of plasminogen and pro-uPA activation. Furthermore, the PA system is only one of several extracellular protease systems involved in invasion and metastasis, and extracellular proteolysis is only one of many factors involved in the overall process of metastasis. A possible explanation for the lack of effect of PAI-1 deficiency on metastasis of MMTV-PymT-induced tumors that we found in this study is, therefore, that the plasminogen activation reaction is not rate limiting for the overall process of metastasis in this model. Similar considerations apply to tumor vascularization. Additionally, there may be a functional overlap between PAI-1 and other protease inhibitors, either directly at the plasminogen activation step, or indirectly at other steps of the cascade. First of all, uPA-catalyzed plasminogen activation may also be inhibited by PAI-2, which primarily is found intracellularly but also appears to have extracellular functions (Montemurro et al., 1999) ; by the protein C inhibitor (Espan˜a et al., 1993) and protease nexin-1 (Scott et al., 1985) , both of which inhibit plasminogen activators among other serine proteases; and by maspin, which is a slow plasminogen activator inhibitor, but nevertheless may play an important physiological role because it promotes internalization of uPA and uPAR (Biliran and Sheng, 2001 ). The maspin gene also blocks tumor progression in a transplantation system based on the MMTV-PymT mouse (Shi et al., 2002) . Secondly, it is highly likely that there is an indirect functional overlap between PAI-1 and inhibitors of plasmin activity, the main plasmin inhibitor being a 2 -antiplasmin (Lijnen, 2001 ). Finally, inhibitors of pro-uPA activation may also substitute for the action of PAI-1; a candidate is hepatocyte growth factor activator inhibitor-1 (HAI-1), which inhibits the membrane-type serine protease matriptase (Lin et al., 1999) , a pro-uPA activator (Takeuchi et al., 2000) . We propose that a functional overlap of PAI-1 with another inhibitor requires that the second inhibitor is present in the tissue, but it need not be upregulated in the absence of PAI-1. We have shown that at least PAI-2 is expressed in the MMTV-PymT-induced primary tumors irrespective of PAI-1 status. Functional overlap between different molecules appears to be a widespread phenomenon and a reason for the lack of spontaneous phenotype often seen in mice made deficient in a single gene. For proteases specifically, we have previously shown that such an overlap exists between the PA system and matrix metalloproteases in wound healing (Lund et al., 1999) . It remains to be investigated whether there is a similar functional overlap between PAI-1 and other protease inhibitors in metastasis of MMTV-PymT-induced tumors, for example, by the use of appropriate double knockout mice or by treatment of the PAI-1 gene-deficient mice with compounds that neutralize potentially overlapping protease inhibitors.
Previous studies have shown that host PAI-1 deficiency leads to reduced angiogenesis in a transplanted murine epithelial tumor model (Bajou et al., 1998 ) and a transplanted murine fibrosarcoma (Gutierrez et al., 2000) , and it was recently reported that angiogenesis in a Matrigel implant assay (McMahon et al., 2001) , an aortic explant assay (Devy et al., 2002) , as well as a retinal model system (Lambert et al., 2001 ) is reduced or absent in PAI-1-deficient mice. There is an apparent discrepancy between the effect of PAI-1 deficiency in those studies and the lack of effect on tumor vascularization in MMTV-PymT-induced breast cancer that we report here, as well as the normal growth and development and the absence of spontaneous macroscopic and microscopic abnormalities in the PAI-1-deficient mice (Carmeliet et al., 1993a, b) . A possible explanation for this discrepancy is that vascularization during development and during growth of endogenous tumors is governed by other processes than those that are provoked during transplanted tumor growth and in some experimental vascularization setups.
We have previously hypothesized that PAI-1 does not inhibit, but on the contrary promotes tumor progression by preventing excessive proteolysis (Andreasen et al., 1986; Kristensen et al., 1990; Dan et al., 1993; Grndahl-Hansen et al., 1993) . The assumption that PAI-1 promotes tumor progression has since been strongly supported by the consistent finding that high PAI-1 levels in tumor tissue are associated with poor prognosis in several types of human cancer (Ja¨nicke et al., 1991; Nekarda et al., 1994; Pedersen et al., 1994; Andreasen et al., 1997) . In human cancer tissue, PAI-1 is often expressed in endothelial cells (Pyke et al., 1991; Bianchi et al., 1995; Hewitt and Dan, 1996) , and as an additional mechanism for a promoting role of PAI-1 in cancer progression, it has been proposed that PAI-1 facilitates tumor angiogenesis (Pepper et al., 1996; Pepper, 2001) . If PAI-1 plays a promoting role in tumor progression, it might be expected that PAI-1 deficiency would result in decreased tumor growth or metastasis. Our results clearly show that this is not the case in MMTV-PymTinduced breast cancer. This may reflect that PAI-1 does not play such a role in this model, but alternatively it may indicate functional overlap between PAI-1 and other protease inhibitors as discussed above.
Abbreviations GAPDH, glyceraldehyde-3-phosphate dehydrogenase; H&E, hematoxylin and eosin; MMTV, mouse mammary tumor virus; PA, plasminogen activation; PAI, plasminogen activator inhibitor; PBS, phosphate-buffered saline; PymT, polyomavirus middle T antigen; tPA, tissue-type plasminogen activator; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type plasminogen activator receptor.
